fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Search » Astrazeneca Pharma India Ltd

Astrazeneca Pharma India Ltd

Updated on September 11, 2019

Stock/Share Code - ASTRAZEN

Astrazeneca Pharma India is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.(Source : 201903 Annual Report Page No: 72)

Below is the details of ASTRAZEN Astrazeneca Pharma India Ltd

Market Cap₹4,702 Cr.
Current Price ₹2,010.6 as on 17 Sep 19
52 Week High / Low Price₹2,398.55 / ₹1,306.05
Face Value₹2
Stock P/E67.59
Book Value₹120.32
Dividend Yield0.00 %
ROCE26.51 %
ROE19.87 %
Sales Growth (3yrs)8.91 %
SectorPharmaceuticals
IndustryPharmaceuticals - Multinational
Listed onBSE  AND  NSE
Company WebsiteCompany Website
Pros: Company is virtually debt free. Company is expected to give good quarter Company has good consistent profit growth of 39.13% over 5 years
Cons: Stock is trading at 15.63 times its book value Though the company is reporting repeated profits, it is not paying out dividend The company has delivered a poor growth of 8.98% over past five years. Company has a low return on equity of 13.76% for last 3 years.

Astrazeneca Pharma India Ltd Price Chart

Astrazeneca Pharma India Ltd Price Chart

Astrazeneca Pharma India Ltd Peer Comparison in Pharmaceuticals

S.No. Name CMP Rs. P/E Mar Cap Rs.Cr. Div Yld % NP Qtr Rs.Cr. Qtr Profit Var % Qtr Sales Var % Sales Qtr Rs.Cr. ROCE %
1. Glaxosmi. Pharma ₹15.05 48.35 ₹20,586.22 Cr. 1.65 ₹113.54 Cr. 27.17 7.11 787.97 31.11
2. Abbott India ₹9,746 40.10 ₹19,440.78 Cr. 0.71 ₹116.94 Cr. 41.92 18.22 998.89 37.36
3. Sanofi India ₹5,793.55 36.36 ₹14,138.35 Cr. 1.37 ₹97.4 Cr. -2.21 9.41 747.90 28.84
4. Pfizer ₹3,250.15 29.74 ₹13,382.81 Cr. 0.77 ₹112.81 Cr. 22.83 6.26 544.40 23.22
5. Proc. Gam. Heal. ₹120.05 8.01 ₹6,830.07 Cr. 10.69 ₹44.08 Cr. -8.76 6.06 233.63 78.16
6. Astrazeneca Phar 67.59 ₹4,701.63 Cr. 0.00 ₹21.52 Cr. 236.78 26.71 204.56 26.51
7. Novartis India ₹64.75 62.57 ₹1,401.57 Cr. 1.76 ₹0.79 Cr. -92.10 -20.85 109.31 7.58

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Astrazeneca Pharma India Ltd Fundamentals

Quarterly Results

Quarterly reports are issued by companies every three months. Most companies have a financial year-end of Mar. 31 and quarters that end on June 30, Sept. 30, Dec. 31 and March 31.

Standalone Figures in Rs. Crores

Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019
Sales138150116127164129151161161215190205
YOY Sales Growth %7.65%3.95%-27.14%-8.64%18.88%-14.47%30.27%26.64%-1.77%67.41%26.25%26.71%
Expenses135135115121129139135152147174184169
Material Cost %32.01%31.27%32.94%35.42%32.54%29.91%28.85%32.46%32.67%29.75%33.04%34.24%
Employee Cost %33.7%25.11%31.57%27.41%22.16%28.88%29.39%25.97%27.86%23.74%31.74%24.8%
Operating Profit3151636-111591541636
OPM %2%10%1%5%22%-8%10%6%9%19%3%17%
Other Income2101523233463
Interest000000000000
Depreciation444444444445
Profit before tax121-2734-121491441834
Tax %19%23%-380%19%20%12%77%30%37%28%-16%36%
Net Profit116-10627-10369291022
EPS in Rs0.326.48-3.822.3210.95-4.141.292.583.6511.643.938.61
NotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotes

Profit & Loss

The profit and loss (P&L) statement is a financial statement that summarizes the revenues, costs and expenses incurred during a specified period, usually a fiscal quarter or year. The P&L statement is synonymous with the income statement. These records provide information about a company's ability or inability to generate profit" by increasing revenue, reducing costs or both. Some refer to the P&L statement as a statement of profit and loss, income statement, statement of operations, statement of financial results or income, earnings statement or expense statement.

Standalone Figures in Rs. Crores

Dec 2007Dec 2008Dec 2009Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019TTM
Sales302353397594531390474517564544571728771
Sales Growth %12.63%16.86%12.22%49.82%-10.56%-26.54%21.4%9.12%9.02%-3.55%5.02%27.55%%
Expenses211241307490501459487528547507525657674
Material Cost %31.28%28.16%30.5%30.17%33.62%39.6%35.06%38.69%35.31%31.99%31.61%31.74%%
Manufacturing Cost %3.39%5.91%3.88%2.1%4.82%5.04%4.92%3.94%3.16%2.79%2.83%2.49%%
Employee Cost %16.28%17.21%20.51%25.33%30.47%38.03%33.86%30.91%30.04%29.8%26.34%27.1%%
Other Cost %18.79%16.89%22.52%24.93%25.39%34.86%28.91%28.66%28.57%28.63%31.11%28.88%%
Operating Profit921139010430-68-13-111637467198
OPM %30%32%23%17%6%-18%-3%-2%3%7%8%10%13%
Other Income101456610236714121616
Interest0500000000000
Depreciation676971210151716151516
Profit before tax951148810129-700-21636447397
Tax %36%35%35%36%32%-27%-0%9%44%41%25%
Net Profit6174586420-90-1-21520265470
EPS in Rs22.0426.9921.3519.257.340.000.000.002.108.0210.3621.7827.83
Dividend Payout %61%51%43%39%44%-0%-0%-0%0%0%0%0%

Compounded Sales Growth

  • 10 Years:: 7.50%
  • 5 Years:: 8.98%
  • 3 Years:: 8.91%
  • TTM:: 27.51%

Compounded Profit Growth

  • 10 Years:: -3.03%
  • 5 Years:: 39.13%
  • 3 Years:: 118.44%
  • TTM:: 161.11%

Return on Equity

  • 10 Years:: 6.25%
  • 5 Years:: 7.94%
  • 3 Years:: 13.76%
  • Last Year:: 19.87%

Balance Sheet

A balance sheet is a financial statement that reports a company's assets, liabilities and shareholders' equity at a specific point in time, and provides a basis for computing rates of return and evaluating its capital structure. It is a financial statement that provides a snapshot of what a company owns and owes, as well as the amount invested by shareholders. It is used alongside other important financial statements such as the income statement and statement of cash flows in conducting fundamental analysis or calculating financial ratios.

Standalone Figures in Rs. Crores

Dec 2007Dec 2008Dec 2009Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Share Capital555555555555
Equity Capital555555555555
Reserves15411114017518495167146151218242296
Borrowings0620000000000
Other Liabilities9011291131157206244261247196215262
Trade Payables4.137.4312.1620.9127.2897.89111.41113.959687.87127.3168.29
Total Liabilities249291236310346306416412403419462563
Fixed Assets3330302732259410197877575
Gross Block82.8381.0682.884.5295.4298.64169.75191.44203.76102.57105.85119.83
Accumulated Depreciation49.7550.752.7857.0663.7374.1175.5390.46106.415.7330.3945
CWIP0002458749126547
Investments000000000000
Other Assets216260206259256208312298299327383481
Inventories23.7834.0135.257.275.185.3795.7686.1376.7357.71113.15118.1
Trade receivables47.0750.1368.2143.7132.327.9652.9342.7783.144354.6379.75
Cash Equivalents111.04143.868.2385.3953.2218.4789.0725.0876.83115.58125.92173.3
Loans n Advances34.0132.3833.9342.4553.0633.0136.87109.2730.3778.8261.5457.99
Other Assets etc00030.242.3743.0437.4235.1432.2532.0728.0451.99
Total Assets249291236310346306416412403419462563

Cash Flows

Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow.

Standalone Figures in Rs. Crores

Dec 2007Dec 2008Dec 2009Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Cash from Operating Activity4082336439-6-1-465738955
Profit from operations92.41115.8691.58104.0231.04-67.3-10.85-12.2617.8750.1147.1980.29
Working Capital Changes-17.09-2.2-23.45.1638.5861.0617.66-32.5842.09-0.24-34.259.81
Taxes paid-35.61-32.02-35.61-44.68-30.90.2-7.61-0.87-2.98-11.77-4.15-35.12
Cash from Investing Activity-352-28-34-16-15-19-40-94
Fixed Assets Purchased-6.84-4.83-7.12-32.28-39.84-18.79-21.63-23.81-9.04-5.65-6.28-18.69
Fixed Assets Sold0.290.290.530.270.910.253.310.240.130.230.030.27
Investments sold0000000000.0100
Cash from Financing Activity-34-54-111-29-29-10860-1000
Net Cash Flow333-768-24-3271-645338-159

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Ratios

Dec 2007Dec 2008Dec 2009Mar 2011Mar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
ROCE %63%71%55%62%15%-53%-12%-13%4%15%19%27%
Debtor Days575263272226413054293540
Inventory Turnover10.4712.2311.4612.868.034.865.235.696.928.096.686.30

Announcements & News

Recent Announcements

Annual Reports

How to Invest in Mutual Funds SIP Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.
  2. Complete your Registration and KYC Process
  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest! Get Started
  4. Invest in Mutual Funds which invests in Astrazeneca Pharma India Ltd & Get More Returns than Bank Deposit

Disclaimer:
All efforts have been made to ensure the information provided here is accurate as per time to time filling by company to exchanges. However, no guarantees are made regarding correctness of data. Investors are advised to validate/check information with exchanges or companies website before making any investment decisions.